Asymchem Laboratories (Tianjin) Co., Ltd. (HKG:6821)

Market Cap	61.90B +40.2%
Revenue (ttm)	7.88B +16.6%
Net Income	1.26B +11.7%
EPS	3.53 +10.0%
Shares Out	n/a
PE Ratio	49.04
Forward PE	34.50
Dividend	1.50 (1.38%)
Ex-Dividend Date	Jun 25, 2026

Volume	535,906
Open	111.10
Previous Close	111.30
Day's Range	107.00 - 113.20
52-Week Range	69.20 - 138.70
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About HKG:6821

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in ke...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 10,617
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6821

Financial Performance

In 2025, HKG:6821's revenue was 6.67 billion, an increase of 14.91% compared to the previous year's 5.80 billion. Earnings were 1.13 billion, an increase of 19.35%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 3, 2026

Data Sources Report a data error